Article ; Online: Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis.
2022 Volume 37, Issue 5, Page(s) e2841
Abstract: Background: The United States Food and Drug Administration has approved drugs that address only autism-related symptoms rather than the underlying impairments. N-Methyl-D-Aspartate receptor antagonists have recently emerged as a promising treatment ... ...
| Abstract | Background: The United States Food and Drug Administration has approved drugs that address only autism-related symptoms rather than the underlying impairments. N-Methyl-D-Aspartate receptor antagonists have recently emerged as a promising treatment option for a variety of neurologic and developmental problems, including autism. Aims: To review (systematically), for the first time, the medical literature that explores the safety in and efficacy of memantine in autism. Methods and procedures: A comprehensive electronic search for relevant randomized controlled trials was conducted in four databases. Using RevMan software, we extracted and pooled data as a risk ratio (RR) or normalized mean differences in an inverse variance strategy. Results: This systematic review and meta-analysis includes five trials. There was no difference in enhancing social responsiveness when compared to placebo, though memantine lowered the likelihood of anxiety (RR = 0.25; 95% Confidence interval: [0.07; 0.87], p = 0.03). However, memantine aggravated impulsive behaviors. Additionally, in another trial that compared memantine added to risperidone versus risperidone added to placebo, memantine was found to be effective and safe. Conclusion: Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders. However, memantine does not improve the core symptoms of autism. Nevertheless, further long-term trials are needed to explore its potential efficacy. |
|---|---|
| MeSH term(s) | Anxiety Disorders/drug therapy ; Autism Spectrum Disorder/drug therapy ; Child ; Excitatory Amino Acid Antagonists/adverse effects ; Humans ; Memantine/adverse effects ; Risperidone/therapeutic use |
| Chemical Substances | Excitatory Amino Acid Antagonists ; Risperidone (L6UH7ZF8HC) ; Memantine (W8O17SJF3T) |
| Language | English |
| Publishing date | 2022-03-21 |
| Publishing country | England |
| Document type | Journal Article ; Meta-Analysis ; Review ; Systematic Review |
| ZDB-ID | 632931-7 |
| ISSN | 1099-1077 ; 0885-6222 |
| ISSN (online) | 1099-1077 |
| ISSN | 0885-6222 |
| DOI | 10.1002/hup.2841 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2192: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.